負(fù)責(zé)公司各項外部合作及復(fù)星凱特在中國的首款CAR-T的商業(yè)化開發(fā),包括銷售、商務(wù)運營、市場、BD、和準(zhǔn)入。
曾任上海復(fù)星醫(yī)藥集團(tuán)戰(zhàn)略部總監(jiān),參與包括復(fù)星凱特合資建立、復(fù)星領(lǐng)智在內(nèi)的各項集團(tuán)內(nèi)重大投資合作項目。
2008至2015年期間于上海交通大學(xué)上海免疫學(xué)研究從事腫瘤免疫及自身免疫病研究。
He’s the Chief Commerical Officer of Fosun Kite Biotechnology Co., Ltd. In charge of Fosun Kite 's various external cooperation and the commercial development of the company's first CAR-T in China, including sales, commercial operations, marketing, access and BD.
He used to be the director of the strategy department of Fosun Pharma, and participated in various major investment cooperation projects within the group, including the establishment of Fosun Kite joint venture and Fosun Lead.
From 2008 to 2015, he was engaged in tumor immunity and autoimmune disease research at Shanghai Institute of Immunology, Shanghai Jiao Tong University.?